1273-GZMK+ T Cells as Biomarkers for Immunotherapy Response
This research identifies granzyme K (GZMK) expression in T cells as a critical biomarker for predicting success in neoadjuvant cancer immunotherapies. By analyzing single-cell data from head and neck cancer patients, the study reveals that GZMK+ progenitor T cells recently recruited from the blood represent a state of high antitumor immunocompetence. Successful treatment outcomes are strongly linked to the efficient differentiation of these cells into active effectors within the tumor microenvironment. Furthermore, the authors developed a GZMK gene signature that accurately forecasts patient…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.